Research programme: tubulin polymerisation inhibitors - EntreMed

Drug Profile

Research programme: tubulin polymerisation inhibitors - EntreMed

Alternative Names: 3,3-Diarylacrylonitriles as tubulin polymerisation inhibitors - EntreMed; CC 4089; CC 5079; ENMD 1420; ENMD 1427; ENMD 1916; Tubulin polymerisation inhibitors - Celgene/EntreMed

Latest Information Update: 19 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celgene Corporation
  • Developer EntreMed
  • Class Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Dec 2008 Discontinued - Preclinical for Cancer in USA (PO)
  • 09 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
  • 06 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top